
Aavantgarde
Developer of a gene therapy technology designed for inherited retinal disorders. The company builds on proprietary Adeno-Associated Viral (AAV) vector platforms to address the gene therapy cargo capac...
Valuation
$0
Share Price
N/A
Total Raised
$211.4M
Last Round
N/A